Rubicon Research IPO closed on October 13, 2025. The ₹1,377.50 crore public issue comprised a fresh issue of ₹500 crore and an offer for sale of ₹877.50 crore, with a price band of ₹461–₹485 per share and a lot size of 30 shares.
The IPO will be listed on both NSE and BSE, with the allotment finalisation on October 14, refunds & credit to Demat on October 15, and the listing date fixed for October 16, 2025.
The Rubicon Research IPO registrar is MUFG Intime India Private Ltd.
Rubicon Research, incorporated in 1999, is a pharmaceutical formulation and drug-development company providing R&D, contract manufacturing (CDMO), and specialty generic solutions for regulated markets such as the US and Canada.
How to Check Rubicon Research IPO Allotment Status Online
Option 1 – BSE Website
Visit https://www.bseindia.com/investors/appli_check.aspx
Select “Equity” under Issue Type
Choose “Rubicon Research Ltd” under Issue Name
Enter your Application Number or PAN
Click “Submit” to view your status
Option 2 – NSE Website
Go to https://www.nseindia.com/invest/check-ipo-allotment-status
Select “Equity” and choose Rubicon Research Ltd
Enter your PAN or Application Number
Click “Submit”
Option 3 – Registrar (MUFG Intime India Private Ltd)
Visit https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Select “Rubicon Research IPO” under Select Company
Enter any of the following: PAN, Application No., or DP/Client ID
Click “Submit” to check status
Rubicon Research IPO Subscription Status (Final Day – 13 Oct 2025)
Company Overview & Financials
Rubicon Research Ltd develops and manufactures specialty pharma and generic formulations, drug-device combinations, and controlled-release technologies. It operates R&D and manufacturing facilities in India and Canada, with about 99% of its revenue from the US market.
For FY 2024-25, the company reported:
Revenue: ~₹12,962
EBITDA Margin: ~21%
Revenue CAGR (FY23–FY25): ~80%